140 related articles for article (PubMed ID: 16133107)
21. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cell-induced activation of adaptive and innate antitumor immunity.
van den Broeke LT; Daschbach E; Thomas EK; Andringa G; Berzofsky JA
J Immunol; 2003 Dec; 171(11):5842-52. PubMed ID: 14634094
[TBL] [Abstract][Full Text] [Related]
23. Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways.
Miyake T; Kumagai Y; Kato H; Guo Z; Matsushita K; Satoh T; Kawagoe T; Kumar H; Jang MH; Kawai T; Tani T; Takeuchi O; Akira S
J Immunol; 2009 Aug; 183(4):2522-8. PubMed ID: 19635904
[TBL] [Abstract][Full Text] [Related]
24. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.
Zhou H; Luo Y; Kaplan CD; Krüger JA; Lee SH; Xiang R; Reisfeld RA
Blood; 2006 Apr; 107(8):3251-7. PubMed ID: 16368879
[TBL] [Abstract][Full Text] [Related]
25. Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties.
Miller G; Pillarisetty VG; Shah AB; Lahrs S; DeMatteo RP
J Immunol; 2003 Apr; 170(7):3554-64. PubMed ID: 12646617
[TBL] [Abstract][Full Text] [Related]
26. CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-γ production in response to mature dendritic cells.
Stojanovic A; Fiegler N; Brunner-Weinzierl M; Cerwenka A
J Immunol; 2014 May; 192(9):4184-91. PubMed ID: 24688023
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of myeloid dendritic cells retrovirally transduced to express mammalian or viral interleukin-10 on cytotoxic T lymphocyte and natural killer cell functions and resistance to tumor growth.
Takayama T; Tahara H; Thomson AW
Transplantation; 2001 May; 71(9):1334-40. PubMed ID: 11397973
[TBL] [Abstract][Full Text] [Related]
28. Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.
James BR; Brincks EL; Kucaba TA; Boon L; Griffith TS
Cancer Immunol Immunother; 2014 Jul; 63(7):685-97. PubMed ID: 24711083
[TBL] [Abstract][Full Text] [Related]
29. Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a
Takeda Y; Azuma M; Funami K; Shime H; Matsumoto M; Seya T
Front Immunol; 2018; 9():496. PubMed ID: 29593736
[No Abstract] [Full Text] [Related]
30. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
31. CX3CR1+ CD8alpha+ dendritic cells are a steady-state population related to plasmacytoid dendritic cells.
Bar-On L; Birnberg T; Lewis KL; Edelson BT; Bruder D; Hildner K; Buer J; Murphy KM; Reizis B; Jung S
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14745-50. PubMed ID: 20679228
[TBL] [Abstract][Full Text] [Related]
32. TLR agonists downregulate H2-O in CD8alpha- dendritic cells.
Porter GW; Yi W; Denzin LK
J Immunol; 2011 Oct; 187(8):4151-60. PubMed ID: 21918198
[TBL] [Abstract][Full Text] [Related]
33. Type I interferon supports primary CD8+ T-cell responses to peptide-pulsed dendritic cells in the absence of CD4+ T-cell help.
Ontiveros F; Wilson EB; Livingstone AM
Immunology; 2011 Apr; 132(4):549-58. PubMed ID: 21255009
[TBL] [Abstract][Full Text] [Related]
34. Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells.
Moriya K; Wakabayashi A; Shimizu M; Tamura H; Dan K; Takahashi H
Cancer Immunol Immunother; 2010 Jul; 59(7):1083-95. PubMed ID: 20221597
[TBL] [Abstract][Full Text] [Related]
35. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
36. The lectin Siglec-G inhibits dendritic cell cross-presentation by impairing MHC class I-peptide complex formation.
Ding Y; Guo Z; Liu Y; Li X; Zhang Q; Xu X; Gu Y; Zhang Y; Zhao D; Cao X
Nat Immunol; 2016 Oct; 17(10):1167-75. PubMed ID: 27548433
[TBL] [Abstract][Full Text] [Related]
37. Antigen presentation capacity and cytokine production by murine splenic dendritic cell subsets upon Salmonella encounter.
Yrlid U; Wick MJ
J Immunol; 2002 Jul; 169(1):108-16. PubMed ID: 12077235
[TBL] [Abstract][Full Text] [Related]
38. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.
Suleman M; Galea S; Gavard F; Merillon N; Klonjkowski B; Tartour E; Richardson J
Vaccine; 2011 Aug; 29(35):5892-903. PubMed ID: 21723900
[TBL] [Abstract][Full Text] [Related]
39. In vitro hematopoiesis produces a distinct class of immature dendritic cells from spleen progenitors with limited T cell stimulation capacity.
Quah B; Ni K; O'Neill HC
Int Immunol; 2004 Apr; 16(4):567-77. PubMed ID: 15039387
[TBL] [Abstract][Full Text] [Related]
40. Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.
Chung Y; Chang JH; Kim BS; Lee JM; Kim HY; Kang CY
Eur J Immunol; 2007 Jun; 37(6):1453-62. PubMed ID: 17474148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
